CAR-T cell therapy embarks on autoimmune disease
Alexandros Rampotas, Johanna Richter, David Isenberg, Claire Roddie
Abstract
Chimeric antigen receptor T cell therapy targeting the B-cell antigen CD19 (CD19CAR-T) has shown remarkable effectiveness against leukaemia/lymphoma following treatment failure with the B-cell targeting monoclonal antibodies (mAbs) Rituximab and Obinatuzumab in combination with chemotherapy [ 1 , 2 ]. B-cell aplasia is a ubiquitous off-tumour-on-target phenomenon of CD19CAR-T [ 3 ].
Topics & Concepts
MedicineAutoimmune diseaseImmunologyCell therapyDiseaseImmunopathologyCellAntibodyPathologyGeneticsBiologyCAR-T cell therapy researchBiosimilars and Bioanalytical MethodsViral Infectious Diseases and Gene Expression in Insects